A Phase 3 interventional study of CTX001 in Beta-Thalassemia, Thalassemia and Genetic Diseases, Inborn, sponsored by Vertex Pharmaceuticals Incorporated. Active, not recruiting at 6 sites in 5 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in beta-Thalassemia with a site in United Kingdom — 2 open to participants now, 7 under way, 5 of them phase 3. beta-Thalassemia · United Kingdom.
Among the 19 studies in beta-Thalassemia with a site in United Kingdom, this one is the 17th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2022, is one of 9 in phase 3, and was the 18th registered.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
Browse beta-Thalassemia studies →2 of the 19 studies in beta-Thalassemia with a site in United Kingdom are open now. Recruiting first, the newest first:
Celgene · Sites in United Kingdom, United States, Australia and 19 more countries
Ages 18+
Vertex Pharmaceuticals Incorporated · Sites in United Kingdom, United States, Belgium and 3 more countries
Ages 2+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 2 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 10
First in 1999; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Median enrollment 72 across the 18 interventional studies, 66 across the 1 observational. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
Vertex Pharmaceuticals Incorporated has 4 studies filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
2 of the studies in beta-Thalassemia with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT06421636Regeneron PharmaceuticalsA Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | 2026-12-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in beta-Thalassemia with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Key Inclusion Criteria:
Diagnosis of TDT as defined by:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive single infusion of CTX001 through central venous catheter.
Biological: CTX001
Administered by intravenous infusion following myeloablative conditioning with busulfan.
Also known as: Exagamglogene autotemcel, Exa-cel
Proportion of Participants who Achieve Transfusion Independence for at Least 12 Consecutive Months (TI12)
Time frame: Up to 24 Months After CTX001 Infusion
Proportion of Participants Achieving at Least 95 Percent (%), 90%, 85%, 75% and 50% Reduction in Annualized Transfusions
Time frame: From Baseline up to 24 Months After CTX001 Infusion
Transfusion Free Duration for Participants who Achieve TI12
Time frame: Up to 24 Months After CTX001 Infusion
Proportion of Alleles With Intended Genetic Modification Present in Peripheral Blood Over Time
Time frame: Up to 24 Months After CTX001 Infusion
Proportion of Alleles With Intended Genetic Modification Present in CD34+ Cells of the Bone Marrow Over Time
Time frame: Up to 24 Months After CTX001 Infusion
Change in Fetal Hemoglobin Concentration Over Time
Time frame: From Baseline (Pre-transfusion) up to 24 Months After CTX001 Infusion
Change in Total Hemoglobin Concentration Over Time
Time frame: From Baseline (Pre-transfusion) up to 24 Months After CTX001 Infusion
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Signing of Informed Consent up to 24 Months After CTX001 Infusion
Proportion of Participants With Engraftment (First day of 3 Consecutive Measurements of Absolute Neutrophil Count [ANC] ≥500 per Microliter [mcgL] on 3 Different Days)
Time frame: Within 42 Days After CTX001 Infusion
Time to Engraftment
Time frame: Up to 24 Months After CTX001 Infusion
Incidence of Transplant-related Mortality (TRM) Within 100 Days After CTX001 Infusion
Time frame: Within 100 Days After CTX001 Infusion
Incidence of TRM Within 12 Months After CTX001 Infusion
Time frame: Within 12 Months After Infusion
Incidence of All-cause Mortality
Time frame: From Signing of Informed Consent up to 24 Months After CTX001 Infusion
Relative Reduction in Annualized Volume and Episodes of RBC Transfusions starting Month 10 After CTX001 infusion
Time frame: From Baseline up to 24 Months After CTX001 Infusion
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Started May 2022 (actual). Primary completion is estimated for Nov 2027, 66 months after the start.
Of 18 phase 3 interventional studies under beta-Thalassemia, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 66 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Exagamglogene autotemcel
Vertex Pharmaceuticals Incorporated →